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Abstract
Purpose: Total hip arthroplasty (THA) is highly successful but some patients will
require later revision surgery. This pilot study evaluates the effects of long‐term
follow‐up for patients undergoing revision hip replacement.
Methods: Consecutive patients undergoing aseptic revision of THA were recruited
from a large orthopaedic unit to a single centre, observational study. Primary out-
comes were changes in patient‐reported scores from pre‐revision to 12 months
post‐surgery. Secondary outcomes were costs during hospital stay up to 6 months
post‐revision. Participants were retrospectively allocated to two groups—those with
regular orthopaedic review prior to revision (Planned revision) or those without
(Unplanned revision).
Results: 52 patients were recruited, 7 were unrevised, one incomplete baseline
questionnaires. There were 25 planned and 19 unplanned revisions with no signifi-
cant differences between groups at baseline. At 12 months, 34 complete data
sets were available for analysis, 17 in each group. Change scores were analysed
with Mann–Whitney U test; none reached statistical significance. There was a
significant difference for length of stay: Planned group 5 days (2–22), Unplanned 11
days (3–86) (Mann–Whitney U test, p ¼ 0.023). No significant differences found for
theatre time or component costs. Resource costs post‐revision surgery are
presented.
Conclusion: This pilot study indicates that some change in methods would be
required for future work. The results show that there may be some financial benefit
from providing long‐term follow‐up of THA but a larger study is needed to explore
these findings and to discuss the impact on recommended guidelines.
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1 | INTRODUCTION
It is known that total hip arthroplasty (THA) is a successful pro-
cedure for end‐stage arthritis of the hip through relief of pain and
restoration of movement and that, once in place, the joint
replacement may be effective for many years (Patel, Pavlou, Mujica‐
Mota, & Toms, 2015). The size of the affected population is
considerable—in England, Wales, Northern Ireland and the Isle of
Man, there are approximately 90,000 primary THA completed each
year (National Joint Registry, 2019). Recent evidence from
Australia, based on registry data from 2003 to 2013, predicts a rise
of 208% on 2013 procedure numbers by 2030 (Ackerman et al.,
2019). Up to 10% of these replacements will require revision during
the lifetime of the recipient (National Joint Registry, 2019). Early
revision, in the first 5 years, is often due to a symptomatic condition
such as infection or dislocation but revision beyond the early period
is more likely to be attributable to other causes such as aseptic
loosening which may be asymptomatic and continues to be the most
common indication for revision of a hip replacement (National Joint
Registry, 2019).
Traditional guidelines, produced by specialist orthopaedic soci-
eties, recommend mid to long‐term follow‐up of this population to
provide ongoing care. ‘Long‐term’ is used in reference to the period
beyond 10 years (mid‐term beyond 5 years) when an assessment of
joint construct and symptoms may identify any damaging changes,
especially asymptomatic ones, and evaluate the need for revision
(British Hip Society, British Orthopaedic Association, & Royal Col-
lege of Surgeons of England, 2019). Planning for revision can
potentially improve the experience and outcomes through damage
limitation and pre‐operative preparation. Currently, the requirement
for long‐term follow‐up is questioned in the United Kingdom and
elsewhere due to changes in materials and construct design, the use
of components with an Orthopaedic Date Evaluation Panel rating,
patient expectations and the economic constraints on many health
services (Cassidy, O Heireamhoin, & Beverland, 2019; Hacking,
Weinrauch, Whitehouse, Crawford, & Donnelly, 2010; Lovelock
et al., 2018).
A survey of practice across the United Kingdom in 2013 showed
that only 43% of the sample of orthopaedic units included were
offering any long‐term follow‐up, beyond 10 years (Smith, 2014).
Many of these had changed practice because of constraints on
service delivery rather than because they had clinical evidence to
support the disinvestment. In a systematic literature review for
evidence of the effectiveness of long‐term follow‐up after THA,
there were no quantitative evaluations of such services amongst the
114 studies included (Smith, Dures, & Beswick, 2019). In the
absence of this information, the research question for this pilot
study was: Is there evidence to suggest a beneficial effect of follow‐
up services for patients undergoing revision hip replacement? The
objectives were to test the logistics of the proposed methods, and to
gather information on patient reported outcomes and associated
costs.
2 | METHODS
2.1 | Study design and participants
The detailed protocol and study design have previously been pub-
lished (Smith, Lenguerrand, Blom, Powell, & Palmer, 2017). This was a
pilot observational study, conducted as a preliminary investigation of
the proposed methods, which took place in a single, large orthopaedic
unit in the United Kingdom. The participants were all those under-
going aseptic revision of THA and were recruited consecutively over
a 12‐month period, with final data collected 12 months after revision
surgery. Inclusion criteria were adults over 18 years, ability to
complete a postal English language questionnaire and more than 5
years between primary and revision arthroplasty.
2.2 | Group allocation
In this study, two groups were constructed retrospectively; there was
no control group. The two groups were ‘Planned revision’ and
‘Unplanned revision’ of the hip replacement. Long‐term follow‐up
was considered as planned orthopaedic review (including x‐ray) of
the hip implant at any time in the period that commenced 5 years
after the primary operation to the present day. This group was cat-
egorised as ‘Planned revision’. The comparator group were those
patients scheduled for revision surgery following an emergency
admission or general practitioner (GP) referral due to problems with
the hip implant. They were considered as those with no orthopaedic
long‐term follow‐up of their hip arthroplasty and/or an ‘Unplanned
revision’. The assignment of each participant to one of these two
groups was retrospectively completed using a variety of data sources
and a decision algorithm (see Figure 1).
2.3 | Data sources used for decision algorithm
1. Hospital patient information system—inpatient and outpatient
attendance data
2. Electronic record of medical notes, including letters to and from
GP and other services
3. Radiology archiving systems—imaging of affected hip joint (e.g.,
the presence of serial images suggests orthopaedic monitoring)
The data gathered from the various sources and knowledge of
participating orthopaedic units were incorporated in the decision
algorithm to allocate participants to one of two groups—‘Planned
revision’ or ‘Unplanned revision’. The ‘12‐month’ cut off from time
from referral to revision surgery was used because of current prac-
tice at the time of this study. There was commonly a 22–24 weeks
wait between GP referral to the orthopaedic service and the first
orthopaedic appointment, and then further screening/results and
waiting for a pre‐operative appointment, adding another 8–10
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weeks. Surgery might take place as soon as 2–3 weeks after the pre‐
operative assessment if no complications arose, hence a total of
approximately nine months from referral to surgery. The choice of a
12‐month cut off was designed to differentiate between those par-
ticipants who came to revision surgery without regular orthopaedic
assessment (Unplanned revision) and those who were in a regular
follow‐up programme or who were being monitored for progression
of potentially damaging changes around the THA (Planned revision).
2.4 | Procedures
The participants in this study were recruited pre‐operatively and
completed a set of patient‐reported outcome measures at that time.
A self‐reported questionnaire was used to capture use of health re-
sources at 6 months after revision surgery. The patient‐reported
outcome measures were repeated 12 months after surgery.
Peri‐operative data were collected from medical records.
2.5 | Primary outcome
The primary clinical outcomes were the difference in patient‐reported
measures from the time of surgery to 12 months post‐surgery; the
joint specific Oxford Hip Score (OHS; Dawson, Dawson, Fitzpatrick,
Carr, & Murray, 1996), the EuroQol EQ‐5D instrument to value
quality of life (EuroQol Group, 2019), and the University of Southern
California at Los Angeles (UCLA) Activity Score (Naal, Impellizzeri, &
Leunig, 2009). For each participant, a change score was constructed
by deduction of the pre‐operative score from the 12‐month score.
The OHS is a widely used score consisting of 12 questions about
pain and function after total hip replacement (score range from zero,
poor outcome, to 48, best outcome). It has been shown to be valid
and reliable for use in revision hip surgery (Dawson et al., 2001).
The EuroQol EQ‐5D consists of a self‐report questionnaire
Euroqol 5‐dimension Score (EQ‐5D‐5L) which comprises five di-
mensions (mobility, self‐care, usual activities, pain/discomfort and
anxiety/depression) and a visual analogue scale Euroqol Visual
Analogue Score (EQ‐VAS) which is a single mark on a scale of 0–100.
The EQ‐5D‐5L dimensions were combined to give a single index
value with reference to the United Kingdom value set, using the time
trade‐off (TTO) method (The EuroQol Group, 2007, p. 21). This
produces a score from 1.0, equivalent to full health, through zero
(death) to   1.0, a state assumed to be worse than death. The value
set for the TTO method was originally constructed from participant
ratings of 10 years in several health states in comparison to full
health and to death. The TTO method was chosen as it has been
shown to be valid for hip revision surgery and use of the United
Identify source of referral for 
revision surgery
General Practitioner/Other
Time from referral to revision 
surgery <12 months
UNPLANNED REVISION
Time from referral to revision 
surgery >12 months
≤2 orthopaedic service 
appointments for affected hip 
prior to revision surgery
UNPLANNED REVISION
>2 orthopaedic service 
appointments for affected hip 







No follow-up pathway or unclear
≤2 orthopaedic service 
appointments for affected hip in 
24 months preceding revision 
surgery
UNPLANNED REVISION
>2 orthopaedic service 
appointments for affected hip in 
24 months preceding revision 
surgery
PLANNED REVISION
F I GUR E 1 Decision algorithm used for retrospective allocation to group
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Kingdom value set is recommended by the National Institute for
Health and Care Excellence (National Institute for Health and Care
Excellence, 2020).
The UCLA activity score consists of 10 statements relating to
level of activity and the participant selects the one level that best
describes their current state (range from 1 to 10 with a high value
representing a more active lifestyle).
2.6 | Secondary outcome
The secondary outcome measure was the cost of revision hip surgery
and the early postoperative period, adopting a health and social care
payer perspective for the economic evaluation.
2.6.1 | Resource use identification and collection
Data were included for the initial inpatient stay for the revision THA
(including operating theatre time, prosthesis and length of stay),
subsequent inpatient stays post discharge at any hospital and
outpatient visits during the first 12 months post‐revision surgery.
The data collected included location, duration and reason for visit.
Volumes for all other resource use were collected using a pa-
tient‐reported questionnaire administered at 6 months post‐surgery
based on a self‐completed resource use logbook. This included non‐
hospital services, medication use, provision of equipment and adap-
tations made to the home, and use of social services. Non‐hospital
services included contacts with GP, practice nurse and district nurse,
and physiotherapy and occupational therapy at home or an outpa-
tient clinic. Social services included home care, meal delivery and
social worker contact. Participants were asked to include medication,
equipment, adaptations, home care and meal provision that were
self‐funded.
2.6.2 | Valuation of resource use
Volumes of resources and unit cost prices were treated separately.
Resources used during the initial hospital stay were valued using unit
costs obtained from the hospital finance department. Cost estimates
for time spent in theatre and admissions to hospital wards included
staff time, overheads, consumables and medications. Prosthesis costs
were taken from consortium supply lists or from direct contact with
the orthopaedic companies supplying components.
For secondary care visits in the 6‐month post‐operative period,
information on the reason for inpatient admission, duration of
episode and clinical expert advice was used to derive healthcare
resource group codes. Healthcare resource groups and outpatient
appointment by clinical speciality were valued using Department of
Health Reference Costs (NHS England and NHS Improvement, 2020).
Non‐hospital services and personal social services were valued
using unit costs for health and social care (Curtis et al., 2020).
Equipment and home adaptations, such as mobility aids, commodes,
toilet frames, grab rails and furniture raisers, were financed by health
and social care but provided to patients on loan, through occupa-
tional therapists and physiotherapists. The useful life of the equip-
ment was assumed to be 2 years and valued as a fraction of
equipment cost proportional to the duration of patient use (12 weeks
post‐surgery). Unit costs were obtained from the equipment supplier
to National Health Service (NHS) Trusts and community services
(Medequip Assistive Technologies Ltd.). Items permanently fitted to
the property, such as grab rails and stair rails, were valued at full cost.
Self‐funded equipment or adaptations were valued as the lowest cost
from three online suppliers. Prescribed medication was valued using
the British National Formulary (The Royal Pharmaceutical Society,
2020). Resource usage and personal costs incurred due to a pre‐
existing medical condition and not directly related to the surgery
were excluded. The unit cost estimates can be seen in Table S1.
2.7 | Statistics and data analysis
This was a pilot study and adopted an exploratory approach to data
analysis. Sample size was not predetermined but it was anticipated
that 180 participants may be eligible, based on historic data from the
orthopaedic unit. Several unanticipated problems led to a reduced
number of eligible participants and consequently, there were insuf-
ficient primary outcome data for a linear mixed method model. Data
are presented with descriptive statistics and tests for the difference
between groups, parametric and non‐parametric as indicated by the
data distribution (Student's t‐test, chi square and Mann–Whitney‐U
test, significance set at p < 0.05; IBM SPSS Statistics 26.0). The
economic evaluation of health benefits is presented as a cost‐
consequences table in view of the small sample size.
2.8 | Ethics
Research ethics approval for this study was granted from the NHS
Health Research Authority (London—Camden and King's Cross
Research Ethics Committee) on 19 April 2016, reference number:
16/LO/0650. All participants gave written informed consent and the
study was conducted in accordance with the Declaration of
Helsinki.
3 | RESULTS
Between 27 June 2016 and 30 June 2017, 110 patients were
screened, 52 gave informed consent and were recruited for the
study. The exclusions were as per protocol (Smith et al., 2017) with
many patients unwilling or unable to complete a questionnaire 12
months after surgery due to age, comorbidity or cognitive status. The
demographics of included participants can be seen in Table 1 and the
flow of data collection, by group, in Figure 2. There were no
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statistically significant differences between groups for any of the
baseline patient characteristics.
Details of the primary reason for revision surgery were extracted
from the discharge letter sent to each participant's GP (Table 2). In
the Planned revision group, most were undertaken for changes noted
on serial X‐rays of the affected hip replacement and in the Unplanned
revision group, most were undertaken because of patient‐reported
pain.
A summary of the demographic details of the 10 participants
with incomplete data sets is presented in Table 3 and shows a male
predominance. Table 4 presents a summary of the baseline patient‐
reported outcome measures for all participants, showing these to be
similar. The primary outcome data were the differences in patient‐
reported outcome scores from before to 12‐month after revision
surgery (Table 5). There were no statistically significant differences
between groups for change scores although the change in EQ‐VAS
approached statistical significance.
The major costs associated with the revision hip replacement and
hospital stay for all participants are summarised to give an average
(median) participant value (Table 6). A notable difference between the
two groups occurs in the costs associated with the length of stay in
hospital as the unplanned revision group were, on average, in hospital








Age in years, mean, range 73.3 (45.8–86.1) 75.5 (46.5–89.2) Student's t test, 0.49
Sex 10 male 9 male Chi Squared, 0.63
15 female 10 female
Laterality 15 right 11 right Chi Squared, 0.89
10 left 8 left







Resource use data 6 
months post surgery
n=22
Data 12 months post 
surgery
n=17
12 month data not returned 
n=5
Deceased n=1






Participants rejoin data 
collection n=2
12 month data not returned 
n=1
Data 12 months post 
surgery 
n=17
Resource use data 6 





No resource use 
data n=2
F I GUR E 2 Data collection from
participants by group
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TAB L E 2 Primary indication for
revision hip arthroplasty





Pain 6 (24%) 11 (58%)
X‐ray changes 13 (52%) 2 (10.5%)
Peri‐prosthetic fracture 0 (0%) 4 (21%)
Dislocation/subluxation 1 (4%) 2 (10.5%)
Adverse reaction to metal debris 5 (20%) 0 (0%)






Age in years, mean, range 72.5 (45.8–81.4) 78.4 (70.2–85.1)
Sex 4 male 2 male
3 female 1 female
Laterality 4 right 3 right
3 left 0 left
Charlson comorbidity index, median, range 3.0 (0.0–6.0) 4.0 (3.0–4.0)













Age in years, mean 73.3 77.5 70.2
Charlson comorbidity index, median, range 2 (2–8) 3 (1–6) 3 (0–6)
Pre‐operative Oxford hip score, median, range 24.0 (6–41) 23.0 (3–48) 20.5 (11–29)
Pre‐operative EQ‐5D‐5L, median, range 0.449 (  0.346 to 0.735) 0.419 (  0.199 to 0.765) 0.430 (0.051–0.721)
Pre‐operative EQ‐VAS median, range 75 (10–90) 75 (20–95) 72.5 (10–95)
Pre‐operative UCLA score, median, range 4 (2–7) 3 (1–7) 4.5 (3–6)
Abbreviations: EQ‐5D‐5L, Euroqol 5‐dimension Score; EQ‐VAS, Euroqol Visual Analogue Score; UCLA, University of Southern California at Los Angeles
activity score.
TAB L E 5 Change in patient‐reported outcome scores from pre‐ to 12 months post‐revision surgery
Patient reported outcome measure
Planned revision, score changes Unplanned revision, score changes
StatisticsNumber with complete data ¼ 17 Number with complete data ¼ 17
Median IQR Range Median IQR Range
Mann–Whitney
U test, p‐value
Φyear Oxford hip score (Basic score 0–48) 13 21   0.2, þ33 11 21   9, þ32 0.50
Φyear EQ‐5D‐5L (Basic score   1.0 to þ1.0) 0.254 0.58   0.51, þ1.11 0.223 0.42   0.5, þ0.66 0.92
Φyear EQ‐VAS (Basic score 0–100) 10 18   10, þ68 0 30   25, þ30 0.05
Φyear UCLA (Basic score 1–10) 0 2   2, þ4 0 2   3, þ4 0.51
Abbreviations: EQ‐5D‐5L, Euroqol 5‐dimension Score; EQ‐VAS, Euroqol Visual Analogue Score; IQR, Interquartile range; UCLA, University of Southern
California at Los Angeles activity score; Φyear, change over one year.
264 - SMITH ET AL.
for longer. The median for the Planned revision was 5 days (range 2–22
days) and for Unplanned revision was 11 days (range 3–86 days), which
was statistically significant (Mann–Whitney U test statistic 333.000,
p¼ 0.02). There was no statistically significant difference between the
median length of time taken for surgery in the two groups (Planned
revision 2.84 h, range 1.14–7.0 h; Unplanned revision 3.04 h, range
1.31–11.0 h; Mann–Whitney U test, p ¼ 0.84).
A total of 38 participants completed the resource use ques-
tionnaire. Some participants completed the 12‐month questionnaire
but not resource use; they found it difficult to concentrate due to
comorbidities or carer responsibilities. The data are presented with
summary values and show that groups were similar apart from an
extended hospital stay for one participant in the Unplanned revision
group (Table 7).
4 | DISCUSSION
This pilot study indicates that changes would be needed in the de-
livery of any similar future study but offers insight into the effect of
long‐term follow‐up services when revision hip arthroplasty is
required. The sample was small but demonstrates some differences in
patient reported quality of life and peri‐operative costs which favour
the use of long‐term follow‐up in this patient population.
The limitations of this work are the size and scope as it was a
one‐centre, pilot study and the number of patients recruited were
fewer than anticipated due to several factors including patient
choice, operational changes, winter pressures and research staff
availability. Maintaining the screening of potential participants and
recruitment of eligible patients was inconsistent over the 12 months
of the study due to staff shortages in research. Of those recruited, a
proportion did not proceed to surgery as anticipated, and there was
further loss to follow‐up through incomplete data. When compared
with those who competed all scores, the only notable difference was
a higher proportion of males in this group (Tables 1 and 3). Future
studies may be advised to avoid lengthy post‐operative question-
naires for this group of patients and maximise the in‐hospital data
collection. In addition, data collection from a large number of hos-
pital units would mitigate for the unforeseen effects that further
reduced recruitment in this pilot study. This information is impor-
tant for future work and contributed to the development of a large,
multi‐centre observational study on the effect of long‐term
TAB L E 6 Cost Consequences analysis for the in‐patient stay
Cost category
Planned revision, costs (£) n ¼ 25 Unplanned revision, costs (£) n ¼ 19
Median IQR Range Median IQR Range
Cost of hospital stay 1135.00 795 454–4994 2497.00 3632 681–19,522
Cost of hip replacement components 1984.62 3135 530–6181 1712.14 1662 774–7361
Cost of time in operating theatre 2726.40 1637 1094–6720 2918.40 1622 1257–10,560
Total costs per patient 6537.47 4322 2892–13,196 8008.56 4771 2713–29,269
Abbreviation: IQR, Interquartile range.
TAB L E 7 Summary of costs from patient‐reported resource use questionnaire in the 6 months post‐surgery
Source of accumulated costs
Resources used per participant (£), median, range
Planned revision n ¼ 22 Unplanned revision n ¼ 16
Use of any community health services since discharge post revision
surgery for reasons related to revision hip replacement
78.92 (0.00–831.78) 89.43 (0.00–525.76)
Inpatient in any hospital or rehabilitation unit since discharge for
reasons related to hip revision
0.00 (0.00–0.00) 0.00 (0.00–17,290.00)
Outpatient visits at any hospital related to hip revision 0.00 (0–304.00) 0.00 (0.00–222.00)
Use of prescribed medication for reasons related to hip revision 0.00 (0.00–51.48) 0.00 (0.00–111.54)
Use of over‐the‐counter medication for reasons related to hip revision 0.00 (0.00–15.00) 0.00 (0.00–18.00)
Changes made to the home (e.g., grip rails and stair lift) or special equipment
provided (e.g., commode, toilet frame, toilet seat and trolley) related to
your hip revision
4.31 (0.00–231.46) 4.79 (0.00–229.00)
Requirement for a home care worker (home help) for reasons related to
your hip revision
0.00 (0.00–390.00) 0.00 (0.00–0.00)
Use of a home delivery food service for reasons related to your hip revision 0.00 (0.00–50.00) 0.00 (0.00–0.00)
Total patient‐reported resource use, median, range 131.96 (1.75–1291) 251.42 (0–17,378)
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follow‐up services after hip and knee replacement (Czoski‐Murray
et al., 2019).
The retrospective allocation of participant to groups (Planned
revision vs. Unplanned revision) employed an algorithm which was
constructed with reference to clinical knowledge by the authors and
orthopaedic colleagues. The variables included time from referral and
frequency of appointments in secondary care. It did not differentiate
the profession of the referrer, which may provide greater insight into
the pre‐revision pathway. It did not attempt to establish if the
participant was on a recommended follow‐up pathway, or if the
participant had adhered to that pathway. Consequently, some par-
ticipants may have been incorrectly assigned to a group. However,
the allocation was seen to be correct in cases where pathways were
known, and the principles incorporated in the algorithm facilitated a
consistent approach that could be employed with larger data sets in
subsequent work.
The EQ‐VAS requires the patient to indicate on a scale how good
or bad they consider their health to be on the day of score comple-
tion and provides well‐validated evidence for health quality (EuroQol
Group, 2019). Those in the Planned follow‐up group showed a
greater improvement over the 12 months after surgery than those
without follow‐up, although it did not reach statistical significance
(p ¼ 0.05). There are many reasons why this score may have shown a
difference between groups, such as lower comorbidity scores or a
shorter hospital stay. However, one of the possibilities is that the
screening, preparation and planned pathway to revision provided by
long‐term follow‐up services allows better management of the
experience for the patient with a quicker return to health than those
without such preparation. This would require further exploration in a
larger study.
The cost consequences comparison table (Table 7) shows some
benefit to care providers of long‐term follow‐up services, primarily
due to the length of stay in hospital which leads to a significant in-
crease in cost if it is prolonged. In this study, the median cost per
patient for hospital stay was £1135.00 for the Planned revision group
compared to £2497.00 for the Unplanned revision group. This was
based on a reference cost for an extra night in hospital of £313.00
(NHS England and NHS Improvement, 2020) and the difference of 6
days in median length of stay. In the United Kingdom, approximately
8000 patients undergo hip revision each year and over 50% of these
are for aseptic indications, as in this study (National Joint Registry,
2019). Based on this data, a 6‐day longer stay in hospital for un-
planned revision of all aseptic cases would cost an estimated £7.5
million per annum. Although this scenario is unlikely, the potential
cost‐savings from providing some long‐term follow‐up to reduce
unplanned revision are substantial. Further work is needed to
confirm or refute this early finding.
In addition to the costs incurred by an increased length of stay,
issues of hospital capacity and bed management are an ongoing, real‐
world problem facing hospital management teams and based on this
data, would be worsened by the prolonged occupancy of those
without follow‐up. A proportion of the unplanned revision group
received emergency surgery which may have contributed to the
length of stay for reasons such as preparing the patient for surgery or
planning for discharge. Emergency revision surgery will always be
needed for some patients but there may be others for whom long‐
term follow‐up of THA would lead to planned elective revision,
thereby minimising the unpredictability of prolonged bed occupancy
and its associated problems.
The decision to undertake revision hip arthroplasty is made jointly
by the orthopaedic surgeon and the patient. The threshold for a sur-
geon depends on many factors such as their own experience, the type
of components and materials used in the primary arthroplasty, the
extent of the damage in the THA and the threat of complete failure of
the joint construct. In this study, the primary indication for revision in
the Planned revision group was X‐ray change, although some may also
have experienced pain (Table 2). This raises a question about the
timing of revision surgery as many surgeons are reluctant to operate
on an asymptomatic patient and prefer to wait until the patient com-
plains of pain. However, as patients often find it hard to distinguish the
source of discomfort until symptoms are severe, their presentation to
orthopaedics from primary care may be delayed, either by the patient
or by the system. An orthopaedic assessment of the THA provides an
opportunity for patient education about symptoms alongside a
knowledgeable assessment of the joint construct. In addition, it can
provide patients with reassurance which in turn affects mental health
and has a social impact, whether that is employment or family re-
sponsibility (Arthritis & Musculoskeletal Alliance, 2018).
The delivery of a service that takes place many years after the
primary procedure raises questions about individual responsibility and
personal attitude—should we be expecting those with a THA to initiate
an orthopaedic assessment? There are divided views within the or-
thopaedic community with some suggesting that the burden of re-
sponsibility lies with care providers to keep track of patients and
others suggest that it should be entirely patient‐driven with no action
until symptoms are such that they re‐present in orthopaedics (Rose,
Dures, & Smith, 2020). A model of service delivery which can offer
rapid access for those with concerns about a joint replacement, in
addition to continuous surveillance for high‐risk patients, may be more
acceptable to service users than no service or too‐frequent reviews,
and may incur fewer problems with patient non‐attendance. For
instance, based on current registry reports, an opt‐in arthroplasty
review 10 years after the primary surgery could provide reassurance
and assessment at the start of the second decade of the joint
replacement. This requires further exploration as many in the ortho-
paedic community consider that the current guidelines of review at 1,
7 and 10 years, and 3‐yearly thereafter are unsustainable but that a
modified service should be offered to the THA patient population
(British Hip Society et al., 2019; Cassidy et al, 2019; Rose et al., 2020).
5 | CONCLUSION
This pilot study has shown that modifications to the methods would be
needed in any further study. The results suggest that there may be
some financial benefit from providing patients with a follow‐up service
266 - SMITH ET AL.
in the long‐term after THA but the effect on patients is unclear from
this small sample. A larger study is needed to explore these findings
and to discuss the impact on current recommended guidelines.
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